Jeffrey Dierks - Oct 3, 2022 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Christian Ulrich, Attorney-in-Fact
Stock symbol
HRMY
Transactions as of
Oct 3, 2022
Transactions value $
-$443,854
Form type
4
Date filed
10/4/2022, 04:07 PM
Previous filing
Aug 23, 2022
Next filing
Nov 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $100K +12.2K $8.22* 12.2K Oct 3, 2022 Direct
transaction HRMY Common Stock Sale -$417K -9.38K -77.07% $44.45 2.79K Oct 3, 2022 Direct F1, F2
transaction HRMY Common Stock Sale -$127K -2.79K -100% $45.47 0 Oct 3, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Stock Option Options Exercise $0 -9.74K -100% $0.00* 0 Oct 3, 2022 Common Stock 9.74K $8.22 Direct F4
transaction HRMY Stock Option Options Exercise $0 -2.43K -49.99% $0.00 2.44K Oct 3, 2022 Common Stock 2.43K $8.22 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.93 to $44.91. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.75. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option vests in five equal annual installments beginning on October 1, 2018.
F5 The stock option vests in five equal annual installments beginning on October 1, 2019.